Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(4.21)
# 391
Out of 5,090 analysts
54
Total ratings
32.5%
Success rate
40.61%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $66 → $75 | $28.13 | +166.62% | 2 | Nov 13, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $10.36 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $69.56 | +26.51% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $18.31 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $45.02 | - | 1 | Jul 17, 2025 | |
| RNA Avidity Biosciences | Reiterates: Overweight | $96 | $71.63 | +34.02% | 5 | Jun 27, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $11.07 | - | 2 | Jun 20, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $220.36 | - | 2 | Jun 10, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $10.18 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $11.12 | - | 4 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $18.20 | -28.52% | 2 | Mar 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.29 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $56.88 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $102.52 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.73 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.63 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $38.78 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $181.30 | +61.06% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $455.48 | -18.77% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.42 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.67 | - | 1 | May 30, 2017 |
Legend Biotech
Nov 13, 2025
Maintains: Overweight
Price Target: $66 → $75
Current: $28.13
Upside: +166.62%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $10.36
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $69.56
Upside: +26.51%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $18.31
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $45.02
Upside: -
Avidity Biosciences
Jun 27, 2025
Reiterates: Overweight
Price Target: $96
Current: $71.63
Upside: +34.02%
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $11.07
Upside: -
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $220.36
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $10.18
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $11.12
Upside: -
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $18.20
Upside: -28.52%
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.29
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $56.88
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $102.52
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.73
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.63
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $38.78
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $181.30
Upside: +61.06%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $455.48
Upside: -18.77%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.42
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $1.67
Upside: -